Details of the Drug Reposition

General Information of This Drug (ID: DMWVCF3)

• Drug Name: Fusidic Acid (DMWVCF3)
• Synonyms: FUCIDIN; Fucidate; Fucithalmic; Fusidate; Fusidine; Ramycin; Diethanolamine fusidate; Fucidate Sodium; Fucidic acid; Fucidin acid; Fuci (TN); Fucibet (TN); Fucicort (TN); Fucidin (TN); Fucidin Cream 2%; Fucidine (TN); Fucithalmic (TN); Fucizon (TN); Fudic (TN); Fusiderm (TN); Fusidin (TN); SQ 16,603; Fusidic acid (USAN/INN); C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
• Therapeutic Class: Antibiotics
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

50 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Peritonitis	DISMCMLQ	N.A.	Approved	[1]
Actinomycosis	DIS7YFRP	N.A.	Approved	[2]
Staphylococcal pneumonia	DIS28ZSZ	N.A.	Approved	[3]
Blepharoconjunctivitis	DIS4PG4J	N.A.	Approved	[4]
Staphylococcus aureus infection	DISK6PTH	N.A.	Approved	[5]
Chlamydiaceae infections	DIS208D8	N.A.	Approved	[6]
Syphilis	DISJ73BS	N.A.	Approved	[7]
Folliculitis	DIS10XOM	N.A.	Approved	[8]
Pseudomonas aeruginosa infectious disease	DISC07AQ	N.A.	Approved	[9]
Dacryocystitis	DISFBZLV	N.A.	Approved	[10]
Listeriosis	DISKMQBM	N.A.	Approved	[11]
Neonatal sepsis	DIS8Q3VE	N.A.	Approved	[12]
Yaws	DISLTH3X	N.A.	Approved	[13]
Typhus	DISJ5JX1	N.A.	Approved	[13]
Trachoma	DIS2WZUR	N.A.	Approved	[13]
Rocky mountain spotted fever	DISFN72S	N.A.	Approved	[13]
Rickettsiosis	DIS4GUSE	N.A.	Approved	[13]
Rickettsialpox	DISEMENW	N.A.	Approved	[13]
Relapsing fever	DISEA4L7	N.A.	Approved	[13]
Q fever	DISK1S90	N.A.	Approved	[13]
Ornithosis	DIS4YMZ8	N.A.	Approved	[13]
Mycoplasma pneumoniae pneumonia	DIS1AW2Z	N.A.	Approved	[13]
Lymphogranuloma venereum	DIS0MMFT	N.A.	Approved	[13]
Inhalational anthrax	DISII8HD	N.A.	Approved	[13]
Gastrointestinal anthrax	DIS7DTI1	N.A.	Approved	[13]
Epidemic louse-borne typhus	DISHV9EH	N.A.	Approved	[13]
Endemic typhus	DIS1D29X	N.A.	Approved	[13]
Cutaneous anthrax	DISA6ECE	N.A.	Approved	[13]
Cholangitis	DIS9U3YN	N.A.	Approved	[13]
Chancroid	DISMVLOF	N.A.	Approved	[13]
Brucellosis	DISEAYGH	N.A.	Approved	[13]
Brill-Zinsser disease	DISG4YLE	N.A.	Approved	[13]
Boutonneuse fever	DISGAGZ3	N.A.	Approved	[13]
Bartonellosis	DISMKP1N	N.A.	Approved	[13]
Acute gonococcal epididymo-orchitis	DISBF6L8	N.A.	Approved	[13]
Acute gonococcal cervicitis	DIS4LKDT	N.A.	Approved	[13]
Bacterial infection	DIS5QJ9S	1A00-1C4Z	Approved	[14]
Bacteremia	DIS6N9RZ	1A73	Approved	[15]
Tularemia	DISF94A2	1B94	Approved	[13]
Anthrax	DISFPT78	1B97	Approved	[16]
Streptococcus infection	DIS04U9T	1B53	Approved	[17]
Paronychia	DIS83SVK	1F23.13	Approved	[18]
Demodex blepharitis	DISDSJDZ	1G07	Approved	[13]
Pneumococcal infection	DIS6SXQD	CA00-CA40	Approved	[19]
Bronchitis	DISBM6EQ	CA20	Approved	[20]
Pneumonia	DIS8EF3M	CA40	Approved	[21]
Acne vulgaris	DISKW8PI	ED80	Approved	[22]
Rosacea	DIS02PWG	ED90.0	Approved	[23]
Urinary tract infection	DISMT6UV	GC08	Approved	[24]
Corneal abrasion	DIS3SD7J	NA06.4	Approved	[25]

2 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Acute gonococcal endometritis	DISZ8BW7	N.A.	Withdrawn	[26]
Allergic conjunctivitis	DISZ5ZJN	9A60.02	Withdrawn	[27]

4 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Bacterial meningitis	DISRP9SL	N.A.	Discontinued in Phase 3	[28]
Rhinoscleroma	DISNSWVK	N.A.	Discontinued in Phase 3	[29]
Keratoconjunctivitis	DISOYCQC	N.A.	Discontinued in Phase 3	[30]
Escherichia coli infection	DISPP65M	1A03	Discontinued in Phase 3	[31]

5 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Scrub typhus	DISRXONX	N.A.	Discontinued in Phase 2	[32]
Bacterial conjunctivitis	DIST79FU	N.A.	Discontinued in Phase 2	[32]
Granuloma inguinale	DISRKXBH	N.A.	Discontinued in Phase 2	[33]
Gonorrhea	DISQ5AO6	1A7Z	Discontinued in Phase 2	[34]
Pharyngitis	DISSN548	CA02.Z	Discontinued in Phase 2	[35]

1 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Anterior uveitis	DISQ7EAD	9A96	Discontinued in Phase 1	[36]

2 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Vibrio cholerae infection	DISW7E3U	1A00	Investigative	[13]
Sinusitis	DISX5NCF	CA0A.Z	Investigative	[37]

References

• [1] An experimental evaluation of the pharmacokinetics of fusidic acid in peritoneal dialysis. J Med Microbiol. 1992 Feb;36(2):71-7.
• [2] [In vitro sensitivity of Actinomyces israelii, Actinobacillus actinomycetem-comitans and Bacteroides melaninogenicus to cephalothin, cephaloridine, gentamicin, fusidic acid and lincomycin]. Int Z Klin Pharmakol Ther Toxikol. 1970 Oct;3(4):318-20.
• [3] Fusidic acid in other infections. Int J Antimicrob Agents. 1999 Aug;12 Suppl 2:S11-5.
• [4] Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists. Ophthalmic Physiol Opt. 2006 Jul;26(4):343-61.
• [5] Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Pat Antiinfect Drug Discov. 2008 Jan;3(1):10-33.
• [6] The in vitro effects of proxymetacaine, fluorescein, and fusidic acid on real-time PCR assays used for the diagnosis of Feline herpesvirus 1 and Chlamydophila felis infections. Vet Ophthalmol. 2011 Sep;14 Suppl 1:5-8.
• [7] Balanoposthitis and Penile Edema: Atypical Manifestations of Primary Syphilis. Sex Transm Dis. 2015 Sep;42(9):524-5.
• [8] Fusidic acid betamethasone lipid cream. Int J Clin Pract. 2016 May;70 Suppl 184:4-13.
• [9] Bacterial profile of diabetic foot infections and antibiotic susceptibility in a specialized diabetes centre in Cameroon. Pan Afr Med J. 2022 May 18;42:52.
• [10] [Susceptibility of drug-resistant staphylococci isolated from different parts of the ocular anterior segment to common ophthalmic antibiotics]. Zhonghua Yan Ke Za Zhi. 2022 Aug 11;58(8):598-605.
• [11] Antimicrobial Resistance of Listeria monocytogenes from Animal Foods to First- and Second-Line Drugs in the Treatment of Listeriosis from 2008 to 2021: A Systematic Review and Meta-Analysis. Can J Infect Dis Med Microbiol. 2022 Oct 7;2022:1351983.
• [12] Microbiological Characteristics and Resistance Patterns in a Neonatal Intensive Care Unit: A Retrospective Surveillance Study. Cureus. 2024 Mar 12;16(3):e56027.
• [13] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [14] Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
• [15] Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65.
• [16] Cationic quaternized aminocalix[4]arenes: cytotoxicity, haemolytic and antibacterial activities. Int J Pharm. 2013 Dec 15;458(1):25-30.
• [17] Impetigo: diagnosis and treatment. Am Fam Physician. 2014 Aug 15;90(4):229-35.
• [18] Extensive pyomyositis secondary to paronychia-related MRSA infection: A case report. Medicine (Baltimore). 2022 Jan 14;101(2):e28431.
• [19] Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist. 1995 Summer;1(2):121-5.
• [20] [Interferon-gamma receptor 1 deficiency in a 19-month-old child: case report and literature review]. Zhonghua Er Ke Za Zhi. 2014 May;52(5):387-91.
• [21] Mycoplasma pneumoniae-associated mucositis. BMJ Case Rep. 2021 Apr 15;14(4):e239086.
• [22] Curcumin/Fusidic Acid Bitherapy Loaded Mixed Micellar Nanogel for Acne Vulgaris Treatment: In Vitro and In Vivo Studies. AAPS PharmSciTech. 2023 Sep 11;24(7):182.
• [23] Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol. 1995 Jan;79(1):42-5.
• [24] Isolation of Staphylococcus aureus Urinary Tract Infections at a Community-Based Healthcare Center in Riyadh. Cureus. 2023 Feb 18;15(2):e35140.
• [25] Antibiotic prophylaxis for corneal abrasion. Cochrane Database Syst Rev. 2022 May 27;5(5):CD014617.
• [26] To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
• [27] FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma
• [28] Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache
• [29] Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
• [30] "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
• [31] Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
• [32] Vitamin E and C to Slow Progression of Common Carotid Artery Plaque Build-Up
• [33] Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
• [34] Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
• [35] Temsirolimus (Torisel) and Erlotinib (Tarceva) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
• [36] Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
• [37] Facial cellulitis associated with Pseudomonas aeruginosa complicating ophthalmic herpes zoster. Dermatol Online J. 2004 Oct 15;10(2):20.